Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | BRAF V600E PTEN R173C |
Therapy | Cetuximab + Encorafenib + Ribociclib |
Indication/Tumor Type | colorectal cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF V600E PTEN R173C | colorectal cancer | sensitive | Cetuximab + Encorafenib + Ribociclib | Preclinical - Patient cell culture | Actionable | In a preclinical study, the combination of Kisqali (ribociclib), Erbitux (cetuximab), and Braftovi (encorafenib) inhibited proliferation and synergistically decreased viability in a patient-derived colorectal cancer cell line harboring BRAF V600E and PTEN R173C (PMID: 39145064). | 39145064 |
PubMed Id | Reference Title | Details |
---|---|---|
(39145064) | CDK4/6 inhibition to resensitize BRAF/EGFR inhibitor in patient-derived BRAF/PTEN-mutant colon cancer cells. | Full reference... |